Part B Insider - 2001 Issue 5
HCFA to Cover PTA/Stent Deployment in Clinical Trials
Subscribe or sign in to view the full article.
Article Overview
This article reviews a HCFA Medicare coverage policy update involving carotid percutaneous transluminal angioplasty and stent deployment in approved clinical trials. It is intended for coding and reimbursement professionals, physicians, and compliance staff who need to understand the scope of the policy shift, the role of FDA Category B investigational device exemption trials, and the fact that local carrier interpretation may still affect payment. The discussion also addresses how the coverage change relates to billing considerations and existing noncoverage language in Medicare policy and federal regulation.
Why This Topic Matters
The article matters because it describes a narrow but important Medicare coverage exception that may affect whether services tied to carotid stent procedures are considered payable in clinical research settings. It also highlights that national policy, local carrier decisions, and billing treatment may not align, which is relevant for accurate claim handling and compliance.
Article Sections
-
Coverage decision and clinical trial context
Explains the Medicare coverage decision, the clinical trial setting, and the broader policy background for carotid angioplasty and stent deployment.
-
Existing noncoverage policy and regulatory background
Summarizes prior Medicare noncoverage language and the related federal regulation discussed in the article.
-
No guarantee of coverage
Describes the limits of the coverage decision, including the continuing role of carrier discretion and local payment interpretation.
-
Coding the PTA/Stent
Addresses the coding and billing implications discussed for carotid angioplasty and stent deployment in the clinical trial context.
What You Will Learn
- How a Medicare coverage decision can affect carotid angioplasty and stent procedures in clinical trials.
- How the article frames the relationship between national policy and local carrier payment decisions.
- What coding and billing topics are discussed in connection with the procedure combination.
- Why clinical trial status and investigational device designation are relevant to coverage review.
Who Should Read This
- Medical coders
- Billing specialists
- Compliance officers
- Physicians
- Reimbursement staff
- Health system administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com